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Capillary leak syndrome (CLS) is complication occurring after
stem cell transplantation (SCT), which consists in a loss of
intravascular ﬂuids into interstitial spaces after endothelial
damage. CLS incidence is around 20% among adults, and so
far unknown in the pediatric population. Risk factors for CLS
are the use of G-CSF as well as the burden of pre-transplant
chemotherapy. We aimed at assessing CLS incidence, risk
factors and impact on survival in a pediatric cohort of
patients.
In this single centre, retrospective study we revised the
clinical charts of all the patients<18 years of age undergoing
SCT between January 2002 and May 2012 at our Institution.
CLS was deﬁned by at least the ﬁrst 2 of the following
criteria: weight gain>3% in 24 hours, positive intake balance
irrespective of diuretic administration, oedemas (ascites,
pleural effusion, pericarditis, peripheral oedema), hypoten-
sion (10% reduction of MAP), hypoalbuminemia
Clinical data were collected in an electronic database.
235 patients underwent 276 SCT procedures in the analyzed
timeframe.
15/276 fulﬁlled criteria for CLS diagnosis (5.4%).
Patients’ characteristics, conditioning regimen, donor type,
stem cell source, CSA administration as GvHD prophylaxis
and G-CSF administration did not represent a risk factor for
CLS.
The probability of developing CLS was signiﬁcantly higher in
patients exhibiting sepsis (14.3% vs 0.6 %,p< 0.01), and pa-
tients developing CLS were at higher risk for developing
acute GvHD in the ﬁrst 30 days after SCT (10.8% vs 1.8%
p<001).
10/15 patients exhibiting CLS required intensive care
treatment.
In 9 patients CLS did not resolve and directly led to death.
CLS deeply impacts on overall survival on day + 100 after
transplantation (pOS 92.3% vs 57.1%, p<0.01), being a strong
predictive factor for day + 100 TRM.
The CLS is an uncommon but severe complication in pedi-
atric SCT recipients.
No pre-transplant risk factors for CLS could be identiﬁed in
our study. Among the post transplant complications, sepsis is
signiﬁcantly associated with the appearance of CLS. Patients
who develop CLS often need an intensive care treatment and
are at high risk for early TRM, as well as for other endothe-
lium derived complications like GvHD.
The biological relation between sepsis, GvHD and CLS
development in terms of cytokine release and endothelial
damage is worth further studies in order to possibly support
new targeted therapies.
257
Results of Hematopoietic STEM CELL Transplantation for
Primary Immunodeﬁciencies in Children in Mexico: A
Multicentric Report
Regina M. Marinez del Campo-Navarro 1, Martin Perez-Garcia 2,
Oscar Gonzalez-Ramella 1, Mariana Campos-Gutierrez 2,
Dinora Aguilar-Escobedo 2, Ana Luisa Orozco-Alvarado 1,
Oscar Gonzalez-Llano 3, Consuelo Mancias-Guerra 3,
Maria de los Angeles del Campo-Martinez 4,Ines Montero-Ponce 4, Felix Gaytan-Morales 5,
Maria Teresa Pompa-Garza 6, Teodoro Muñoz-Ronquillo 6,
Raquel Amador-Sanchez 7, Alberto Olaya-Vargas 2. 1 Hospital
Civil de Guadalajara Dr. Juan I Menchaca, Guadalajara, Mexico;
2 Instituto Nacional de Pediatria, Mexico City, Mexico;
3Hospital Universitario de Nuevo Leon, Monterrey, Mexico;
4 Centro Medico Nacional la Raza, Mexico City, Mexico;
5Hospital Infantil de Mexico, Mexico City, Mexico; 6 UMAE #
25, Centro Médico Nacional Noreste IMSS, Monterrey, Mexico;
7Hospital General Gabriel Mancera IMSS, Mexico City, Mexico
Introduction: Hematopoietic stem cell transplantation
(HSCT) is the deﬁnitive treatment for some primary immu-
nedeﬁciencies (PID). In 2010 all the pediatric HCT Centers in
Mexico formed the “Mexican Association of Pediatric Stem
Cell Transplantation and Cellular Therapy”. This represents
the ﬁrst report of the association describing the clinical
outcome in HSCT for PID.
Material and Methods: Between January 1998 to March
2013 all PID patients in whom a HSCT was performed in 7
pediatric HCT centers in Mexico, were retrospectively
analyzed.
Results: A total of 57 patients were included. Average age
was 29 months (range 2 to 158). Time from diagnosis until
transplantation was 20 months (range 1 to 110). Diagnosis
included severe combined immunodeﬁciency in 30% (n¼17),
Wiskott-Aldrich Syndrome in 24% (n¼14), Griscelli-syn-
drome in 10% (n¼6), Shwachman-Diamonn 2% (n¼1), Ché-
diak-Higashi syndrome in 2% (n ¼1), others PIDs (in 32%
n¼18). Graft source included: related bone marrow (RBM) in
7% (n¼4), unrelated cord blood in 72% (n¼41), and mobilized
peripheral blood (PMB), including one haploidentical case, in
21% (n¼12). Median cell dose by settings was as follows: in
RBM median mononuclear cell dose was 2.34x108/kg and
median CD34 cell dose was 2.48x106/kg. In PMB median
nucleated cell dose was 8.6 x108/kg and median CD34 cell
dose was 6.3x106/kg, whereas in UCB Median Nucleated cell
dosewas 2.9x108/kg andmedian CD34 cell dosewas 2.1x106/
kg. In all but 1 case, GVHD prophylaxis was given. Condi-
tioning regimens included myeloablative in 63% of patients
(N¼36) and non-myeloablative in 37% (n¼21). Engraftment
occurred in 63% of patients (n¼36). The average time for
neutrophil engraftment was 20 days (range from 8 to 54).
Fourteen patients (24%) developed an II-IV grades aGVHD,
whereas cGvHD was presented only in 7 cases (12%). Trans-
plant related mortality was 26% considering deaths before
day 100. The main causes of death were infection and graft
failure. Overall survival of all cases was 61%.
Conclusion: This is the ﬁrst report of HSCT for PID children in
Mexico. The mean source of Hematopoietic stem cells used
was UCB (71%) with good results in our population. Early
diagnosis and prompt performance of SCT with an optimal
donor and conditioning regimen contributed to the favorable
outcomes.258
Umbilical Cord Blood Transplantation Can be an Effective
Therapy for Patients with Primary Immunodeﬁciency
Diseases Who Lack an HLA-Matched Related Donor
Caridad Martinez 1, William Shearer 2, Jordan Orange 2,
Howard Rosenblatt 3, Kathryn Leung 1, Swati Naik 1,
Stephen Gottschalk 4, Carl Allen 1, Nabil Ahmed 1, Ghadir Sasa 1,
Malcolm K. Brenner 5, Helen E. Heslop 5, Ann M. Leen 4,
Imelda C. Hanson 2, Robert A. Krance 5. 1 Center for Cell and
Gene Therapy, Baylor College of Medicine, Texas Children’s
Hospital, Houston, TX; 2 Immunology, Allergy and
Rheumatology, Baylor College of Medicine, Texas Children’s
